#USA #New York #Faruqi & Faruqi #Aquestive Therapeutics #AQST

Investigation Alert: Faruqi & Faruqi Probes Claims Against Aquestive Therapeutics

In recent developments within the securities market, Faruqi & Faruqi, LLP, a prominent national law firm specializing in securities litigation, has launched an investigation into potential claims involving Aquestive Therapeutics, Inc. (NASDAQ: AQST). The firm is particularly focused on helping investors who have incurred substantial losses related to their investments in Aquestive's stock and options.

Significant Stock Decline

On January 25, 2026, shares of Aquestive Therapeutics experienced a drastic decline of nearly 40% during intraday trading. This significant drop was triggered by a critical announcement from the U.S. Food and Drug Administration (FDA). The FDA highlighted several deficiencies in the New Drug Application (NDA) submitted by Aquestive for its product, Anaphylm, a sublingual film designed for the urgent treatment of severe allergic reactions and anaphylaxis.

This revelation raised serious questions regarding the NDA's approvability before the pivotal action date of January 31, 2026, as the undisclosed deficiencies halted discussions about essential measures, including labeling and post-marketing controls necessary for a successful approval process.

Investors Encouraged to Act

James (Josh) Wilson, a Senior Partner at Faruqi & Faruqi, is urging investors who may have suffered losses due to the recent developments to reach out directly. He emphasizes the importance of understanding one's legal rights, especially as the situation unfolds further. He invites those affected to contact him directly at 877-247-4292 or 212-983-9330 (Ext. 1310) to discuss their options.

The firm, with a robust track record since its establishment in 1995, has been dedicated to recovering substantial funds for investors across various cases. Notably, Faruqi & Faruqi has helped clients recover hundreds of millions of dollars over the years, underscoring its commitment to investor rights and legal recourse.

Handling Pressures in Securities Litigation

Faruqi & Faruqi’s investigation into Aquestive Therapeutics is not an isolated case; rather, it reflects the increasing scrutiny that companies may face in the pharmaceuticals sector, particularly when regulatory bodies like the FDA highlight potential issues with product submissions. For shareholders, this incident highlights the critical nature of timely information about company operations and regulatory matters that can directly affect stock performance.

With looming deadlines and significant investor interest in biotech stocks, staying informed about regulatory updates is essential for stakeholders.

For further insights or to learn more about the ongoing investigation into Aquestive Therapeutics, investors are encouraged to visit Faruqi & Faruqi's official webpage dedicated to this matter, where they can find more details and guidance on how to proceed. The firm assures clients that all communications will be treated with the highest level of confidentiality, further enhancing trust as they navigate through these potentially tumultuous times.

Conclusion

As the January 31 decision date approaches, all eyes will be on Aquestive Therapeutics and the FDA’s forthcoming announcements. Investors looking for legal advice or support in light of this investigation are encouraged not to hesitate in reaching out, as timing could be crucial in taking any necessary action. Faruqi & Faruqi's proactive approach illustrates their dedication to representing the interests of investors and ensuring they are well-informed in the complex landscape of securities litigation.